Contact
searchSearch
HMP Global
Login

EGFR Videos

Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses the final overall survival results from the Alliance A081105 ALCHEMIST trial evaluating adjuvant erlotinib after complete resection of stage IB-IIIA EGFR-mutant non-small cell lung cancer (NSCLC). Originally...
Ramaswamy Govindan, MD, discusses the final overall survival results from the Alliance A081105 ALCHEMIST trial evaluating adjuvant erlotinib after complete resection of stage IB-IIIA EGFR-mutant non-small cell lung cancer (NSCLC). Originally...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Joel Neal, MD
Videos
Amivantamab Plus Lazertinib Improves Survival in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer
06/18/2026
Joel Neal, MD
Joel Neal, MD, discusses updated results from CHRYSALIS-2 Cohort C evaluating first-line amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced NSCLC.
Joel Neal, MD, discusses updated results from CHRYSALIS-2 Cohort C evaluating first-line amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced NSCLC.
Joel Neal, MD, discusses updated...
06/18/2026
Oncology
Ramón Salazar, MD, PhD
Videos
Anti-EGFR–First Strategy Demonstrates Superior Initial Disease Control in Patients With Metastatic Colorectal Cancer
06/09/2026
Ramon Salazar, MD, PhD
Ramón Salazar, MD, PhD, discusses results from the phase 3 CR-SEQUENCE trial showing that first-line panitumumab-based therapy significantly improved response rates and progression-free survival compared with a bevacizumab-first strategy in...
Ramón Salazar, MD, PhD, discusses results from the phase 3 CR-SEQUENCE trial showing that first-line panitumumab-based therapy significantly improved response rates and progression-free survival compared with a bevacizumab-first strategy in...
Ramón Salazar, MD, PhD,...
06/09/2026
Oncology
Jonathan Riess, MD
Videos
Osimertinib Plus Datopotamab Deruxtecan Demonstrates Clinical Activity After First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
04/08/2026
Jonathan Riess, MD
Jonathan Riess, MD, discusses results from the ORCHARD phase 2 substudy showing that osimertinib plus datopotamab deruxtecan demonstrated encouraging clinical activity and durable responses in patients with EGFR-mutated advanced non-small...
Jonathan Riess, MD, discusses results from the ORCHARD phase 2 substudy showing that osimertinib plus datopotamab deruxtecan demonstrated encouraging clinical activity and durable responses in patients with EGFR-mutated advanced non-small...
Jonathan Riess, MD, discusses...
04/08/2026
Oncology
Danny Nguyen, MD
Videos
FDA Expands Amivantamab With Once-Monthly Subcutaneous Dosing
04/01/2026
Danny Nguyen, MD
Danny Nguyen, MD, discusses the FDA approval of once-monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated metastatic non-small cell lung cancer, highlighting the simplified administration schedule, reduced infusion-related...
Danny Nguyen, MD, discusses the FDA approval of once-monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated metastatic non-small cell lung cancer, highlighting the simplified administration schedule, reduced infusion-related...
Danny Nguyen, MD, discusses the...
04/01/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
Molecular Profiling Refines Anti-EGFR Rechallenge in Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses updated results from theCAVE-2 GOIM trial showing that comprehensive ctDNA profiling identified patients most likely to benefit from anti-EGFR rechallenge, reinforcing the importance of molecular...
Stefania Napolitano, MD, PhD, discusses updated results from theCAVE-2 GOIM trial showing that comprehensive ctDNA profiling identified patients most likely to benefit from anti-EGFR rechallenge, reinforcing the importance of molecular...
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
CAVE-2 Evaluates Cetuximab Rechallenge Plus Avelumab in Molecularly Selected Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating cetuximab rechallenge with or without avelumab in patients with liquid biopsy–selected RAS/BRAF wild-type metastatic colorectal cancer, aiming to...
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating cetuximab rechallenge with or without avelumab in patients with liquid biopsy–selected RAS/BRAF wild-type metastatic colorectal cancer, aiming to...
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Benjamin Besse, MD, PhD
Conference Coverage
First-Line Amivantamab Plus Lazertinib Demonstrates Promise in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
10/21/2024
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD, discusses early analysis results from the MARIPOSA study which demonstrated that amivantamab plus lazertinib has promising antitumor activity in patients with advanced EGFR-mutated NSCLC.
Benjamin Besse, MD, PhD,...
10/21/2024
Oncology
Suresh Ramalingam, MD
Conference Coverage
Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer
06/02/2024
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.
Suresh Ramalingam, MD, discussed...
06/02/2024
Oncology

Recent News

FDA Approval
FDA Approves Gedatolisib Plus Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer
07/14/2026
Stephanie Holland
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy progression based on...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy progression based on...
The FDA approved gedatolisib in...
07/14/2026
Oncology
FDA Approval
FDA Grants Full Approval to Selpercatinib for RET Fusion-Positive Solid Tumors
07/14/2026
Stephanie Holland
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional...
07/14/2026
Oncology
News
De-escalated Paclitaxel Plus Trastuzumab and Pertuzumab Yields Excellent Long-Term Outcomes in HER2-Positive Breast Cancer
07/14/2026
Stephanie Holland
Results from a prespecified secondary analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel plus trastuzumab and pertuzumab produced excellent 5-year outcomes in patients with stage II to III HER2-positive...
Results from a prespecified secondary analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel plus trastuzumab and pertuzumab produced excellent 5-year outcomes in patients with stage II to III HER2-positive...
Results from a prespecified...
07/14/2026
Oncology
FDA Approval
FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome
07/13/2026
Stephanie Holland
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a...
07/13/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma
07/10/2026
Emily Estrada
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved...
07/10/2026
Oncology
News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use